No Data
No Data
No Data
No Data
No Data
邁博藥業-B:2023年度報告
Futu NewsApr 18 04:30 ET · Announcements
Maibo Pharmaceutical-B (02181.HK): net loss of 209 million yuan in 2023
On March 26, Ge Longhui | Maibo Pharmaceutical-B (02181.HK) announced that for the year ended December 31, 2023, the Group's revenue increased 55.9% year-on-year to RMB 87.161 million, mainly due to a sharp increase in drug sales revenue during the reporting period compared to last year. Losses attributable to company owners were approximately RMB 209 million, while losses attributable to company owners during the same period last year were approximately RMB 211 million, with a basic loss of RMB 0.05 per share.
Gelonghui FinanceMar 26 07:58 ET
Maibo Pharmaceutical-B (02181) announced 2023 results, operating revenue of about 87.161 million yuan, a year-on-year increase of 55.9%
Maibo Pharmaceutical-B (02181) announced its 2023 results, with revenue of about 87.161 million yuan, a year-on-year increase...
Zhitong FinanceMar 26 07:48 ET
MABPHARM-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Futu NewsMar 26 07:43 ET · Announcements
Maibo Pharmaceutical-B (02181.HK) will hold a board meeting on March 26 to approve the annual results
Gelonghui March 13 | Maibo Pharmaceutical-B (02181.HK) issued an announcement. The board of directors of the company will hold a board meeting on March 26, 2024 to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended December 31, 2023.
Gelonghui FinanceMar 13 04:42 ET
Some Mabpharm Limited (HKG:2181) Shareholders Look For Exit As Shares Take 41% Pounding
The Mabpharm Limited (HKG:2181) share price has fared very poorly over the last month, falling by a substantial 41%. The drop over the last 30 days has capped off a tough year for shareholders, wit
Simply Wall StJan 24 17:00 ET
No Data
No Data